TrialMultiple sclerosis (Houndmills, Basingstoke, England)2025

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.

Krzysztof W Selmaj et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.